Kite Pharma Inc. (KITE) 65.44 $KITE Wall Street
Post# of 64074
Posted On: 02/28/2015 7:59:09 PM
Kite Pharma Inc. (KITE) 65.44 $KITE
Wall Street's Current Play: 'Immunotherapy Of Cancer'
Chris Lacoursiere - at Seeking Alpha - Thu Feb 26, 10:39AM CST
KITE: 65.44 (-2.05), PPHM: 1.41 (+0.03), JUNO: 46.92 (-0.68)
Billionaire George Soros Just Bought These 3 Stocks: Should You?
George Budwell, The Motley Fool - Motley Fool - Sat Feb 21, 11:07AM CST
Billionaire superinvestor George Soros is among the most closely watched figures in the investing world because he's been stunningly successful at consistently picking winners, and perhaps more importantly, avoiding big losers for a long period of...
AGN: 232.74 (+0.34), ACT: 291.36 (+1.58), KITE: 65.44 (-2.05), AMGN: 157.72 (-1.25)
Immuno-Oncology Promises Continued Wealth And Health: LifeTech Capital's Stephen Dunn
Life Sciences Report - Seeking Alpha - Fri Feb 20, 11:11AM CST
Immuno-oncology-disabling cancer's defenses so that a patient's own immune system can seek it out and destroy it-took center stage in the drug development world in 2014. Stephen Dunn of LifeTech Capital believes that preeminence will continue in...
BLCM: 23.22 (+0.17), KITE: 65.44 (-2.05), PFE: 34.32 (-0.27), MRK: 58.54 (-0.42), JUNO: 46.92 (-0.68), BMY: 60.92 (-0.54), CBMG: 29.99 (-0.01), NVS: 102.40 (-0.60)
Kite Pharma Establishes Manufacturing Capabilities to Support Development and Commercialization of CAR and TCR Cancer Immunotherapy Products
GlobeNewswire - Thu Feb 19, 7:07AM CST
Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that it has entered into a lease agreement for a commercial manufacturing facility in El Segundo, California, which is adjacent to Los Angeles International Airport. Kite also recently secured a lease for a clinical manufacturing facility in Santa Monica, California. The two facilities will not only support the planned clinical trials of Kite's product candidates, but also will prepare Kite for the commercial launch and supply of its lead product candidate, KTE-C19, anticipated in 2017.
KITE: 65.44 (-2.05)
IPO Stock Watch: Health Care IPO Market Losing Grip
at Investor's Business Daily - Tue Feb 17, 1:21PM CST
The health care IPO market, after a blazing 2014, is showing signs of illness. Three small IPOs planned for this week, all hailing from the health care sector, are trying once again after previously postponing their offerings. They plan to raise a...
KITE: 65.44 (-2.05), ONCE: 57.59 (-2.66), INOV: 31.06 (-0.34), NVTA: 18.68 (-0.20), BLPH: 12.00 (+0.55)
Track What Biological Products Companies Are Up To: Special Research on Gilead, Halozyme, Heska, Idera, and Kite Pharma
PR Newswire - Tue Feb 17, 7:50AM CST
Editor Note: For more information about this release, please scroll to bottom.
HALO: 15.07 (-0.21), IDRA: 4.87 (-0.27), HSKA: 21.50 (-0.17), KITE: 65.44 (-2.05), GILD: 103.53 (-0.66)
Be Careful: These Biotechs Have Run Too Far Too Fast
Motley Fool Staff - Motley Fool - Mon Feb 16, 10:13AM CST
In biotechnology, stocks sometimes get a bit too far in front of themselves. When that happens, shares can take a big dip; so we asked three Motley Fool experts to weigh in on which stocks they think have climbed too much, too quickly. : On the...
JNJ: 102.51 (-0.29), PCYC: 215.93 (-1.89), JPM: 61.28 (-0.30), GILD: 103.53 (-0.66), KITE: 65.44 (-2.05), ABBV: 60.50 (-0.02), JUNO: 46.92 (-0.68), NVS: 102.40 (-0.60), CELG: 121.53 (-1.82)
Amgen's Skin Cancer Drug to Face FDA Advisory Panel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 3:10PM CST
Amgen's (AMGN) experimental skin cancer treatment, talimogene laherparepvec, is scheduled to face twin FDA advisory committees on Apr 29, 2015.
BMRN: 107.07 (-1.77), KITE: 65.44 (-2.05), MRK: 58.54 (-0.42), AMGN: 157.72 (-1.25)
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
OCAT: 7.2200 (-0.0800), VCEL: 3.60 (unch), PSTI: 3.04 (-0.01), NBS: 3.76 (-0.07), GSK: 47.42 (-0.42), IMUC: 0.57 (-0.02), KITE: 65.44 (-2.05), BAX: 69.15 (+0.48), ONCE: 57.59 (-2.66), JUNO: 46.92 (-0.68), ATHX: 2.59 (+0.02), CUR: 3.76 (-0.02)
Will Kite Pharma (KITE) Disappoint this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 9:40AM CST
Kite Pharma, Inc. (KITE) is expected to report fourth-quarter 2014 results on Feb 13.
ACT: 291.36 (+1.58), KITE: 65.44 (-2.05), AMGN: 157.72 (-1.25), ACOR: 33.84 (-1.72)
Not For The Faint Of CAR-T: The CAR-T Landscape In Early 2015
EP Vantage - Seeking Alpha - Fri Feb 06, 1:26PM CST
This is an extract from a longer report. If you followed last year's explosion of enthusiasm in CAR therapies you might have assumed that this was a super-novel approach that had just burst onto the scientific stage. In fact work on the synthetic...
BLUE: 95.32 (-0.90), CLRB: 2.83 (+0.14), BLCM: 23.22 (+0.17), KITE: 65.44 (-2.05), JUNO: 46.92 (-0.68), NVS: 102.40 (-0.60)
Northwest Has A Differentiated Technology Platform In The Emerging Immuno-Oncology Landscape
Smith On Stocks - Seeking Alpha - Fri Feb 06, 11:08AM CST
Investment Overview Linda Powers was invited to the 7th Annual Phacilitate Immunotherapy Forum in Washington D.C. to speak on the potential role of personalized immunotherapy drugs in the treatment of cancer. She was prominently featured in the ...
NWBO: 7.37 (-0.09), KITE: 65.44 (-2.05), JUNO: 46.92 (-0.68)
14 IPOs You Wish You Bought in 2014 (And Made a Killing On)
at The Street - Thu Feb 05, 7:36AM CST
Getting in on a hot IPO may prove difficult for most retail investors. That doesn't mean there aren't gains to be made. Here are the best performing IPOs in 2014.
ZFGN: 38.65 (-0.09), GPRO: 41.98 (-2.68), CLDN: 18.15 (+0.37), ZEN: 24.72 (+0.09), ASPX: 67.24 (-3.07), TNET: 36.34 (-0.32), NVRO: 41.83 (-1.10), OCUL: 35.77 (+0.71), RDUS: 42.65 (-2.67), ALDR: 26.88 (-0.86), IRMD: 14.50 (+0.01), KITE: 65.44 (-2.05), TUBE: 13.82 (-4.12), VBLT: 4.04 (-0.15)
KITE Pharma - A Standout IPO In 2014 With Even Better Returns To Come In 2015
Financial Markets Wizard - Seeking Alpha - Wed Feb 04, 12:24PM CST
2014 was a record-breaking year for initial public offerings (IPOs). Businesses as wide ranging as furniture retailers, fast food outlets and digital technology firms began trading on the stock market. This proved to be a feast for the writers of...
KITE: 65.44 (-2.05)
Kite Pharma Expands and Strengthens Leadership Team
PR Newswire - Tue Feb 03, 3:30PM CST
Kite Pharma, Inc., (Nasdaq: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced the appointments of Salah D. Kivlighn, Ph.D., as Vice President, Marketing, and Anthony J. Polverino, Ph.D., as Vice President, Research. Dr. Kivlighn will play a critical role spearheading the Company's marketing strategy. He will report to Cynthia M. Butitta, Chief Financial Officer and Chief Operating Officer. Dr. Polverino will lead the research and development of various eACT(TM) candidates. He will report to Margo R. Roberts, Ph.D., Chief Scientific Officer.
KITE: 65.44 (-2.05)
Kite Pharma to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 3:30PM CST
Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that Arie Belldegrun, M.D., FACS, Kite's President and Chief Executive Officer, will present a corporate overview at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015 at 1:30 p.m. Eastern Time at the Waldorf Astoria in New York City. Dr. Belldegrun will also take part in the panel Personalizing Oncology Treatments at 8:00 a.m. Eastern Time, on the same day.
KITE: 65.44 (-2.05)
Bellicum Pharmaceuticals: Has The Bell Finally Tolled For Cancer?
Looking For Diogenes - at Seeking Alpha - Mon Feb 02, 2:43PM CST
BLUE: 95.32 (-0.90), BLCM: 23.22 (+0.17), KITE: 65.44 (-2.05), JUNO: 46.92 (-0.68), NVS: 102.40 (-0.60), CELG: 121.53 (-1.82)
Advaxis: Legit Reasons to Take Another Look at Under-Appreciated Cancer Immunotherapy
at The Street - Tue Jan 27, 8:53AM CST
The hiring of a key Merck scientist and potential for combination cancer immunotherapy explain the recent rebound in Advaxis' stock price.
ADXS: 9.00 (-0.73), KITE: 65.44 (-2.05), MRK: 58.54 (-0.42), JUNO: 46.92 (-0.68)
Kite Pharma (KITE) in Focus: Stock Tumbles 9.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 7:56AM CST
Kite Pharma saw a big move last session as the company’s shares fell below its volatile price range of $71.03 to $87.62 since Jan 8
KITE: 65.44 (-2.05), ALXN: 180.37 (-2.74)
Kite Pharma Announces Expanded Agreement with Tel Aviv Sourasky Medical Center and Pioneering Researcher Professor Zelig Eshhar to Develop Novel Chimeric Antigen Receptor (CAR) Approaches for Cancer Immunotherapy
GlobeNewswire - Thu Jan 22, 7:10AM CST
Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that the Company has expanded its agreement with Tel Aviv Sourasky Medical Center to research and develop novel approaches to CAR T cell therapy, the technology underlying Kite's most advanced programs in cancer immunotherapy. Under the agreement, Kite will collaborate with Professor Zelig Eshhar, Ph.D., the leading pioneer in CAR T cell research and Chair of Immunology Research within the Tel Aviv Sourasky Medical Center's Division of Research and Development.
KITE: 65.44 (-2.05)
Wall Street's Current Play: 'Immunotherapy Of Cancer'
Chris Lacoursiere - at Seeking Alpha - Thu Feb 26, 10:39AM CST
KITE: 65.44 (-2.05), PPHM: 1.41 (+0.03), JUNO: 46.92 (-0.68)
Billionaire George Soros Just Bought These 3 Stocks: Should You?
George Budwell, The Motley Fool - Motley Fool - Sat Feb 21, 11:07AM CST
Billionaire superinvestor George Soros is among the most closely watched figures in the investing world because he's been stunningly successful at consistently picking winners, and perhaps more importantly, avoiding big losers for a long period of...
AGN: 232.74 (+0.34), ACT: 291.36 (+1.58), KITE: 65.44 (-2.05), AMGN: 157.72 (-1.25)
Immuno-Oncology Promises Continued Wealth And Health: LifeTech Capital's Stephen Dunn
Life Sciences Report - Seeking Alpha - Fri Feb 20, 11:11AM CST
Immuno-oncology-disabling cancer's defenses so that a patient's own immune system can seek it out and destroy it-took center stage in the drug development world in 2014. Stephen Dunn of LifeTech Capital believes that preeminence will continue in...
BLCM: 23.22 (+0.17), KITE: 65.44 (-2.05), PFE: 34.32 (-0.27), MRK: 58.54 (-0.42), JUNO: 46.92 (-0.68), BMY: 60.92 (-0.54), CBMG: 29.99 (-0.01), NVS: 102.40 (-0.60)
Kite Pharma Establishes Manufacturing Capabilities to Support Development and Commercialization of CAR and TCR Cancer Immunotherapy Products
GlobeNewswire - Thu Feb 19, 7:07AM CST
Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that it has entered into a lease agreement for a commercial manufacturing facility in El Segundo, California, which is adjacent to Los Angeles International Airport. Kite also recently secured a lease for a clinical manufacturing facility in Santa Monica, California. The two facilities will not only support the planned clinical trials of Kite's product candidates, but also will prepare Kite for the commercial launch and supply of its lead product candidate, KTE-C19, anticipated in 2017.
KITE: 65.44 (-2.05)
IPO Stock Watch: Health Care IPO Market Losing Grip
at Investor's Business Daily - Tue Feb 17, 1:21PM CST
The health care IPO market, after a blazing 2014, is showing signs of illness. Three small IPOs planned for this week, all hailing from the health care sector, are trying once again after previously postponing their offerings. They plan to raise a...
KITE: 65.44 (-2.05), ONCE: 57.59 (-2.66), INOV: 31.06 (-0.34), NVTA: 18.68 (-0.20), BLPH: 12.00 (+0.55)
Track What Biological Products Companies Are Up To: Special Research on Gilead, Halozyme, Heska, Idera, and Kite Pharma
PR Newswire - Tue Feb 17, 7:50AM CST
Editor Note: For more information about this release, please scroll to bottom.
HALO: 15.07 (-0.21), IDRA: 4.87 (-0.27), HSKA: 21.50 (-0.17), KITE: 65.44 (-2.05), GILD: 103.53 (-0.66)
Be Careful: These Biotechs Have Run Too Far Too Fast
Motley Fool Staff - Motley Fool - Mon Feb 16, 10:13AM CST
In biotechnology, stocks sometimes get a bit too far in front of themselves. When that happens, shares can take a big dip; so we asked three Motley Fool experts to weigh in on which stocks they think have climbed too much, too quickly. : On the...
JNJ: 102.51 (-0.29), PCYC: 215.93 (-1.89), JPM: 61.28 (-0.30), GILD: 103.53 (-0.66), KITE: 65.44 (-2.05), ABBV: 60.50 (-0.02), JUNO: 46.92 (-0.68), NVS: 102.40 (-0.60), CELG: 121.53 (-1.82)
Amgen's Skin Cancer Drug to Face FDA Advisory Panel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 3:10PM CST
Amgen's (AMGN) experimental skin cancer treatment, talimogene laherparepvec, is scheduled to face twin FDA advisory committees on Apr 29, 2015.
BMRN: 107.07 (-1.77), KITE: 65.44 (-2.05), MRK: 58.54 (-0.42), AMGN: 157.72 (-1.25)
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
OCAT: 7.2200 (-0.0800), VCEL: 3.60 (unch), PSTI: 3.04 (-0.01), NBS: 3.76 (-0.07), GSK: 47.42 (-0.42), IMUC: 0.57 (-0.02), KITE: 65.44 (-2.05), BAX: 69.15 (+0.48), ONCE: 57.59 (-2.66), JUNO: 46.92 (-0.68), ATHX: 2.59 (+0.02), CUR: 3.76 (-0.02)
Will Kite Pharma (KITE) Disappoint this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 9:40AM CST
Kite Pharma, Inc. (KITE) is expected to report fourth-quarter 2014 results on Feb 13.
ACT: 291.36 (+1.58), KITE: 65.44 (-2.05), AMGN: 157.72 (-1.25), ACOR: 33.84 (-1.72)
Not For The Faint Of CAR-T: The CAR-T Landscape In Early 2015
EP Vantage - Seeking Alpha - Fri Feb 06, 1:26PM CST
This is an extract from a longer report. If you followed last year's explosion of enthusiasm in CAR therapies you might have assumed that this was a super-novel approach that had just burst onto the scientific stage. In fact work on the synthetic...
BLUE: 95.32 (-0.90), CLRB: 2.83 (+0.14), BLCM: 23.22 (+0.17), KITE: 65.44 (-2.05), JUNO: 46.92 (-0.68), NVS: 102.40 (-0.60)
Northwest Has A Differentiated Technology Platform In The Emerging Immuno-Oncology Landscape
Smith On Stocks - Seeking Alpha - Fri Feb 06, 11:08AM CST
Investment Overview Linda Powers was invited to the 7th Annual Phacilitate Immunotherapy Forum in Washington D.C. to speak on the potential role of personalized immunotherapy drugs in the treatment of cancer. She was prominently featured in the ...
NWBO: 7.37 (-0.09), KITE: 65.44 (-2.05), JUNO: 46.92 (-0.68)
14 IPOs You Wish You Bought in 2014 (And Made a Killing On)
at The Street - Thu Feb 05, 7:36AM CST
Getting in on a hot IPO may prove difficult for most retail investors. That doesn't mean there aren't gains to be made. Here are the best performing IPOs in 2014.
ZFGN: 38.65 (-0.09), GPRO: 41.98 (-2.68), CLDN: 18.15 (+0.37), ZEN: 24.72 (+0.09), ASPX: 67.24 (-3.07), TNET: 36.34 (-0.32), NVRO: 41.83 (-1.10), OCUL: 35.77 (+0.71), RDUS: 42.65 (-2.67), ALDR: 26.88 (-0.86), IRMD: 14.50 (+0.01), KITE: 65.44 (-2.05), TUBE: 13.82 (-4.12), VBLT: 4.04 (-0.15)
KITE Pharma - A Standout IPO In 2014 With Even Better Returns To Come In 2015
Financial Markets Wizard - Seeking Alpha - Wed Feb 04, 12:24PM CST
2014 was a record-breaking year for initial public offerings (IPOs). Businesses as wide ranging as furniture retailers, fast food outlets and digital technology firms began trading on the stock market. This proved to be a feast for the writers of...
KITE: 65.44 (-2.05)
Kite Pharma Expands and Strengthens Leadership Team
PR Newswire - Tue Feb 03, 3:30PM CST
Kite Pharma, Inc., (Nasdaq: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced the appointments of Salah D. Kivlighn, Ph.D., as Vice President, Marketing, and Anthony J. Polverino, Ph.D., as Vice President, Research. Dr. Kivlighn will play a critical role spearheading the Company's marketing strategy. He will report to Cynthia M. Butitta, Chief Financial Officer and Chief Operating Officer. Dr. Polverino will lead the research and development of various eACT(TM) candidates. He will report to Margo R. Roberts, Ph.D., Chief Scientific Officer.
KITE: 65.44 (-2.05)
Kite Pharma to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 3:30PM CST
Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that Arie Belldegrun, M.D., FACS, Kite's President and Chief Executive Officer, will present a corporate overview at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015 at 1:30 p.m. Eastern Time at the Waldorf Astoria in New York City. Dr. Belldegrun will also take part in the panel Personalizing Oncology Treatments at 8:00 a.m. Eastern Time, on the same day.
KITE: 65.44 (-2.05)
Bellicum Pharmaceuticals: Has The Bell Finally Tolled For Cancer?
Looking For Diogenes - at Seeking Alpha - Mon Feb 02, 2:43PM CST
BLUE: 95.32 (-0.90), BLCM: 23.22 (+0.17), KITE: 65.44 (-2.05), JUNO: 46.92 (-0.68), NVS: 102.40 (-0.60), CELG: 121.53 (-1.82)
Advaxis: Legit Reasons to Take Another Look at Under-Appreciated Cancer Immunotherapy
at The Street - Tue Jan 27, 8:53AM CST
The hiring of a key Merck scientist and potential for combination cancer immunotherapy explain the recent rebound in Advaxis' stock price.
ADXS: 9.00 (-0.73), KITE: 65.44 (-2.05), MRK: 58.54 (-0.42), JUNO: 46.92 (-0.68)
Kite Pharma (KITE) in Focus: Stock Tumbles 9.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 7:56AM CST
Kite Pharma saw a big move last session as the company’s shares fell below its volatile price range of $71.03 to $87.62 since Jan 8
KITE: 65.44 (-2.05), ALXN: 180.37 (-2.74)
Kite Pharma Announces Expanded Agreement with Tel Aviv Sourasky Medical Center and Pioneering Researcher Professor Zelig Eshhar to Develop Novel Chimeric Antigen Receptor (CAR) Approaches for Cancer Immunotherapy
GlobeNewswire - Thu Jan 22, 7:10AM CST
Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that the Company has expanded its agreement with Tel Aviv Sourasky Medical Center to research and develop novel approaches to CAR T cell therapy, the technology underlying Kite's most advanced programs in cancer immunotherapy. Under the agreement, Kite will collaborate with Professor Zelig Eshhar, Ph.D., the leading pioneer in CAR T cell research and Chair of Immunology Research within the Tel Aviv Sourasky Medical Center's Division of Research and Development.
KITE: 65.44 (-2.05)
(0)
(0)Scroll down for more posts ▼